GSK (BSX) stock surged early Wednesday after the pharma giant reported adjusted earnings of 58 cents per share on $9.48 billion in fourth-quarter sales.
↑ X NOW PLAYING The Weight-Loss Drug Market Is Hot. Which Medical Stock Will Win The Battle For Supremacy?Analysts polled by FactSet expected GSK to earn 49 cents per share on $9.54 billion in sales.
In the year-earlier period, GSK reported earnings of 74 cents a share on $10.25 billion in sales.
For the year, the company guided to 3% to 5% sales growth and 6% to 8% core operating growth. The company also projects 6% to 8% growth in core earnings per share. Analysts forecasted earnings of $4.54 a share and $42.64 billion in sales.
GSK also bumped its 2031 sales outlook and now projects more than 40 billion pounds in sales, up from more than 38 billion pounds previously. That translates to roughly $50.05 billion, up from $47.55 billion, based on today's exchange rates.
In premarket trades on the stock market today, GSK stock charged 6.5% higher to 37.09.
More to follow.
YOU MAY ALSO LIKE:
Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares
RFK Jr. Clears A Key Hurdle To Head Up HHS. Why His Nomination Is A Biotech Black Box.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
Want To Get Quick Profits And Avoid Big Losses? Try SwingTrader
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。